Unichem Laboratories jumps on getting ANDA approval for Quetiapine Extended-Release Tablets

Unichem Laboratories is currently trading at Rs. 284.50, up by 6.05 points or 2.17% from its previous closing of Rs. 278.45 on the BSE.

Unichem Laboratories
Unichem Laboratories

The scrip opened at Rs. 280.70 and has touched a high and low of Rs. 284.70 and Rs. 277.60 respectively.

The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 322.00 on 19-Jan-2022 and a 52 week low of Rs. 197.50 on 22-Nov-2021.

Last one week high and low of the scrip stood at Rs. 284.80 and Rs. 271.60 respectively. The current market cap of the company is Rs. 2004.45 crore.

The promoters holding in the company stood at 50.93%, while Institutions and Non-Institutions held 11.03% and 38.04% respectively.

Unichem Laboratories has received ANDA approval for its Quetiapine Extended-Release Tablets USP, 50 mg, 150 mg, 200 mg, 300 mg, and 400 mg from the United States Food and Drug Administration (USFDA) to market a generic version of SEROQUEL XR (Quetiapine) Tablet, Extended Release, 50 mg, 150 mg, 200 mg, 300 mg, and 400 mg of AstraZeneca Pharmaceuticals LP.

Quetiapine Extended-Release Tablets are indicated for the treatment of Schizophrenia, Bipolar disorder and adjunctive treatment of Major Depressive Disorder (MDD). The product will be commercialized from Unichem’s Goa Plant.

Unichem Laboratories is an international, integrated, specialty pharmaceutical company.